API Innovation Center
The API Innovation Center (APIIC) is a nonprofit organization dedicated to strengthening national health security by reshoring the production of Active Pharmaceutical Ingredients (APIs) to the United States. Through a public-private partnership model, APIIC collaborates with government, industry, and academia to advance technology and optimize under-utilized manufacturing facilities, aiming to build a more resilient pharmaceutical supply chain. The center is committed to ensuring reliable access to essential medicines by fostering innovation, research, and workforce development.
API Innovation Center
What We Do
The continuous flow manufacturing process can significantly improve drug quality, address shortages of essential medicines, accelerate time to market, and strengthen the overall manufacturing competitiveness of the U.S.
In collaboration with the Glioblastoma Foundation and Apertus Pharmaceuticals, APIIC is working to produce high-quality U.S.-made lomustine, a chemotherapy treatment for glioblastoma, to reduce patient costs and ensure supply availability.
Key People
Tony Sardella
Founder & Chair
Kevin Webb
Chief Operating Officer
Don Lohman
Chief Legal & Administrative Officer
Aaron Willard
Chief Partnership Officer
Natalie de Graaf
VP & GM of Data, AI, and ML Solutions for Health & National Security
Gerren McHam
VP, Government and External Affairs
News & Updates
APIIC received a $14 million grant from the U.S. Department of Health and Human Services to bolster U.S. pharmaceutical manufacturing independence.
APIIC received $9.55 million in funding from the state of Missouri to advance its mission to reshore API production.
PharmaVoice referenced APIIC's research and efforts to bolster U.S. pharmaceutical manufacturing, highlighting the need to address underutilization in existing facilities.
APIIC was featured in Supply Chain Brain for Anthony Sardella’s testimony on the underutilization of U.S. generic pharmaceutical manufacturing sites.
The API Innovation Center was featured in Pharma Manufacturing for its role in strengthening the biopharma supply chain.
On November 13, 2024, APIIC hosted its 2nd annual plenary event to advance the goal of reshoring 25% of small molecule API production to the U.S. within five years.